S&P Futures
4,272.75 -4.00 (-0.09%) Dow Futures
33,944.00 -19.00 (-0.06%) Nasdaq Futures
13,473.25 -20.00 (-0.15%) Russell 2000 Futures
1,989.50 +0.40 (+0.02%) Crude Oil
88.18 +0.07 (+0.08%) Gold
1,776.60 -0.10 (-0.01%)
Interpace Biosciences, Inc. (IDXG)
Chart Events
Performance Outlook
| Previous Close | 2.1500 |
| Open | 2.1250 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 800 |
| Day's Range | 2.0000 - 2.1250 |
| 52 Week Range | 1.6700 - 10.3300 |
| Volume | |
| Avg. Volume | 3,683 |
| Market Cap | 8.46M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1170 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IDXG
Related Research
- Interpace Biosciences, Inc.Analyst Report: Quest Diagnostics IncorporatedQuest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.RatingFair ValueEconomic Moat28 days agoMorningstar
- GlobeNewswire
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding (DSO) decreased by 15% PARSIPPANY, NJ, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2022 and provided a business and financial update. Second quarter Net Revenue was $9.
- GlobeNewswire
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our N
- GlobeNewswire
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tools for personal lab automation, it will optimize next generation sequencing (NGS) library preparation utilizing its digital microfluidics (DMF) technology. Also working in conjunction with Miroculus and Interpace Biosciences will be Twist Biosci
